Berry Wealth Group LP Purchases New Position in IQVIA Holdings Inc. (NYSE:IQV)

Berry Wealth Group LP purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 2,297 shares of the medical research company’s stock, valued at approximately $531,000.

Several other large investors have also added to or reduced their stakes in the business. Commonwealth Equity Services LLC lifted its position in shares of IQVIA by 3.6% during the 3rd quarter. Commonwealth Equity Services LLC now owns 20,753 shares of the medical research company’s stock worth $4,083,000 after buying an additional 726 shares in the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its position in shares of IQVIA by 1.0% during the 3rd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 41,765 shares of the medical research company’s stock worth $8,217,000 after buying an additional 400 shares in the last quarter. Xponance Inc. lifted its position in shares of IQVIA by 1.3% during the 3rd quarter. Xponance Inc. now owns 40,882 shares of the medical research company’s stock worth $8,044,000 after buying an additional 512 shares in the last quarter. Pinnacle Associates Ltd. lifted its position in shares of IQVIA by 65.6% during the 3rd quarter. Pinnacle Associates Ltd. now owns 1,678 shares of the medical research company’s stock worth $330,000 after buying an additional 665 shares in the last quarter. Finally, Raymond James & Associates lifted its position in shares of IQVIA by 4.4% during the 3rd quarter. Raymond James & Associates now owns 832,515 shares of the medical research company’s stock worth $163,797,000 after buying an additional 35,448 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on IQV shares. StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Guggenheim lowered shares of IQVIA from a “buy” rating to a “neutral” rating in a research note on Thursday, February 15th. Leerink Partnrs reiterated an “outperform” rating on shares of IQVIA in a research note on Monday, February 26th. UBS Group lifted their price objective on shares of IQVIA from $240.00 to $300.00 and gave the company a “buy” rating in a research note on Thursday, February 15th. Finally, SVB Leerink began coverage on shares of IQVIA in a research report on Monday, February 26th. They set an “outperform” rating and a $290.00 price target for the company. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average price target of $256.80.

IQVIA Trading Down 0.6 %

IQVIA stock traded down $1.32 during mid-day trading on Wednesday, hitting $230.45. The company’s stock had a trading volume of 266,136 shares, compared to its average volume of 955,001. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.86 and a quick ratio of 0.86. The stock has a market cap of $41.83 billion, a price-to-earnings ratio of 31.80, a price-to-earnings-growth ratio of 2.28 and a beta of 1.50. The business has a 50 day moving average price of $245.15 and a 200-day moving average price of $223.79. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.84 EPS for the quarter, beating the consensus estimate of $2.82 by $0.02. The firm had revenue of $3.87 billion during the quarter, compared to the consensus estimate of $3.80 billion. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The company’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.54 earnings per share. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.12 EPS for the current year.

Insider Activity

In related news, insider Kevin C. Knightly sold 8,607 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the transaction, the insider now owns 5,251 shares in the company, valued at $1,313,642.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other IQVIA news, insider Eric Sherbet sold 1,000 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the sale, the insider now owns 20,836 shares in the company, valued at $5,031,894. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Kevin C. Knightly sold 8,607 shares of the company’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the completion of the sale, the insider now owns 5,251 shares in the company, valued at approximately $1,313,642.67. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 41,285 shares of company stock valued at $10,331,003. Insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.